KSKen Swenerton

Ken Swenerton

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ken Swenerton has a total of 33 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Adult lifetime alcohol consumption and invasive epithelial ovarian cancer risk in a population-based case–control study

    by Linda S. Cook, Andy C.Y. Leung, Kenneth Swenerton, Richard P. Gallagher, Anthony Magliocco, Helen Steed, Martin Koebel, Jill Nation, Sima Eshragh, Angela Brooks-Wilson, et al.


  • Open Access

    Histotype predicts the curative potential of radiotherapy: the example of ovarian cancers

    by K. D. Swenerton, J. L. Santos, C. B. Gilks, M. Köbel, P. J. Hoskins, F. Wong, N. D. Le

    Background: To explore the influence of ovarian cancer histotype on the effectiveness of adjuvant radiotherapy (RT). Methods: A review of a population-based experience included all referred women with no reported macroscopic residuum following primary surgery who underwent adjuvant platin-based chemotherapy (CT), with or without sequential RT, and for whom it was possible to assign histotype according to the contemporary criteria. Results: Seven hundred and three subjects were eligible, of these 351 received RT. For those with apparent stage I and II tumors, the cohort with clear cell (C), endometrioid (E), and mucinous (M) disease who additionally received RT exhibited a 40% reduction in disease-specific mortality and a 43% reduction in overall mortality. Conclusions: The curability of those with stage I and II C-, E-, and M-type ovarian carcinomas was enhanced by RT-containing adjuvant therapy. This benefit did not extend to those with stage III or serous tumors. These findings necessitate reassessments of the role of RT and of the nonselective surgical and CT approaches that have characterized ovarian cancer care.


  • Open Access

    HER2 overexpression and amplification is present in a subset of ovarian mucinous carcinomas and can be targeted with trastuzumab therapy

    by Jessica N McAlpine, Kimberly C Wiegand, Russell Vang, Brigitte M Ronnett, Anna Adamiak, Martin Köbel, Steve E Kalloger, Kenneth D Swenerton, David G Huntsman, C Blake Gilks, et al.

    The response rate of ovarian mucinous carcinomas to paclitaxel/carboplatin is low, prompting interest in targeted molecular therapies. We investigated HER2 expression and amplification, and the potential for trastuzumab therapy in this histologic subtype of ovarian cancer.


  • Open Access

    Kisspeptin and GPR54 immunoreactivity in a cohort of 518 patients defines favourable prognosis and clear cell subtype in ovarian carcinoma

    by Leah M Prentice, Christian Klausen, Steve Kalloger, Martin Köbel, Steven McKinney, Jennifer L Santos, Challayne Kenney, Erika Mehl, C Blake Gilks, Peter Leung, et al.

    Background: Kisspeptins and their G-protein coupled receptor, GPR54 are required for GnRH release and have been associated with anti-metastatic tumour cell behaviour in model systems. The latter might suggest that their overexpression would be associated with a better prognosis in cancer. However, kisspeptin/GPR54 interactions (autocrine, paracrine, and/or endocrine) could also impact tumour behaviour in a negative manner. Here, for the first time, we associate the immunoreactivity of the kisspeptin/GPR54 ligand-receptor pair with favourable prognosis in a large cohort of ovarian carcinomas.Methods: Immunohistochemical analysis for kisspeptin and GPR54 was performed on a tissue microarray (TMA) consisting of 518 early stage ovarian carcinomas, all with linked clinical outcome data. The TMA was scored using a staining intensity scale of 0 (negative), +1 (mild-moderate), and +2 (strong). Strong staining cases were considered either kisspeptin or GPR54 positive and designated as 1, while all other cases were considered negative and designated 0. All statistical analysis was conducted using two-sided tests and a p value equal to or less than 0.05 was considered significant.Results: Kisspeptin and GPR54 immunoreactive cases show a favourable prognosis in univariable disease specific survival (p = 0.0023, p = 0.0092), as well as in overall survival (p = 0.0006, p = 0.0002). Furthermore, kisspeptin is an independent marker for favourable prognosis as determined by multivariable disease specific (p = 0.0046) and overall survival analysis (p = 0.0170), while GPR54 is an independent marker for overall survival only (p = 0.0303). Both kisspeptin positive and GPR54 positive cases are strongly associated with the ovarian carcinoma clear cell subtype (p < 0.0001, p < 0.0001), and GPR54 is significantly associated with favourable prognosis in overall survival within the clear cell subtype (p = 0.0102).Conclusion: Kisspeptin and GPR54 immunoreactivity are significantly associated with favourable prognosis in both disease specific and overall survival, as well as being significantly associated with the clear cell ovarian carcinoma subtype, thereby creating the first independent prognostic biomarkers specific for ovarian clear cell carcinomas.


  • Open Access

    Kisspeptin and GPR54 immunoreactivity in a cohort of 518 patients defines favourable prognosis and clear cell subtype in ovarian carcinoma

    by Leah M Prentice, Christian Klausen, Steve Kalloger, Martin Köbel, Steven McKinney, Jennifer L Santos, Challayne Kenney, Erika Mehl, C B Gilks, Peter Leung, et al.